Zokinvy
What Zokinvy is used for
Zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of Hutchinson-Gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous LMNA mutation with progerin-like protein accumulation or a homozygous or compound heterozygous ZMPSTE24 mutation.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Zokinvy
- Active substance
- lonafarnib
- Disease area
- Progeria; Laminopathies
- Medicine group
- Other alimentary tract and metabolism products
- Marketing authorisation holder
- Integral Pharma Solutions EU Limited
- Authorised in the EU since
- 2022
Official information
In the USA
Same active substance: Zokinvy
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Zokinvy used for?
Zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of Hutchinson-Gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous LMNA mutation with progerin-like protein accumulation or a homozygous or compound heterozygous ZMPSTE24 mutation.
What is the active substance in Zokinvy?
Zokinvy contains lonafarnib.
Who makes Zokinvy?
The EU marketing authorisation holder is Integral Pharma Solutions EU Limited.
Is Zokinvy an orphan medicine?
Yes. Zokinvy is designated an orphan medicine in the EU, for a rare disease (Progeria; Laminopathies).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU